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IntroductIon
Bupivacaine is a local anaesthetic belonging to the 
amide group synthesised in 1963. The 50:50 racemic 
mixture of bupivacaine consists of the R (+) and S 
(-) enantiomer, the latter being less toxic (1). It is a 
high potent anaesthetic with long lasting effects and 
its potency is proportional to the toxic effects on the 
cardiovascular and central nervous system. R (+) 
bupivacaine is seven times more potent in blocking 
sodium channels than the S (-) enantiomer (2). 
 In 1998, Weinberg showed the successful 
resuscitation in rats with lipid emulsion following 
local anaesthetic overdose (3). Furthermore a 
paper in 2003 showed similar results in Dogs and 
concluded that infusing a lipid emulsion during 
resuscitation from bupivacaine induced cardiotoxicity 
substantially increased survival in Dogs and improved 
haemodynamics (4). These results led to the use of 
lipid emulsion in humans. 
case report
Patient is a three month old male child, 5.9 kilograms, 
with a history of bilateral inguinal hernia since 
birth. Past medical and surgical history was not 
significant. Physical examination was unremarkable. 
Child was admitted for an elective bilateral inguinal 
herniotomy. 
 A non eventful surgery under general anaesthesia 
with, halothane, atracurium, fentanyl and morphine 
was undertaken. 
 On completion of the procedure, bupivacaine 
(0.5%) 5ml and lignocaine (2%) 5mls were mixed 
and 4 mls were injected subcutaneously on bilateral 
herniotomy sites. Epinephrine was not included in 
the injectate. Within five minutes of administration, 
child started convulsing, generalised tonic clonic in 
nature. 
 Simultaneously the child’s ECG showed an 
initial bradyarrythmia with a heart block, followed 
by premature ventricular complexes, ventricular 
tachycardia, ventricular fibrillation and ventricular 
tachycardia again. 
 A diagnosis of bupivacaine toxicity was 
entertained and the patient was commenced on 
9mls of lipovenous bolus followed by an infusion at 
0.25ml/kg/min of the same. 
 Subsequently the child was given dexamethasone 
2mg, hydrocortisone 20mg and sodium thiopentone 
5mg. 
 The child was then transferred to ICU. On 
admission he convulsed thrice. Initially the child had 
muscular spasms which lasted a few minutes followed 
by generalised tonic clonic convulsions. Vital signs 
were as follows; a temperature of 37 .8°C, heart rate 
184 beats per minute, respiratory rate 67 breaths per 
minute and a blood pressure of 110/50mmhg. The 
random blood sugar was 4mmol/1. The patient was 
maintained on mechanical ventilation. Intravenous 
midazolam and phenytoin was administered 
to control the seizures but without success, and 
subsequently was given two doses of diazepam after 
which the seizures settled. The ECG monitor at this 
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suMMary
anaesthetic agents used locally can be toxic especially if given as an inappropriate 
dose or route. Lipid infusion has been demonstrated in several animal models to 
successfully resuscitate bupivacaine induced toxicity. We present a case of successful use 
of 26% lipid infusion to resuscitate a paediatric patient with a presumed subcutaneous 
injection of bupivacaine and lignocaine which led to neurological and cardiologic 
consequences. 
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time showed a sinus tachycardia. 
 The intravenous lipid was continued and four 
hours post admission to ICU, the child was seizure 
free. Baby was extubated as spontaneous breathing 
resumed. Few hours post extubation, he was allowed 
to breast feed. Overnight, the child remained stable 
though was febrile for 24 hours. Investigations were 
essentially normal, including a haemogram, C- 
reactive protein, urea electrolytes and creatinine. 
 Following morning child was feeding well, 
with no seizures reported. Heart rate and rhythm 
were normal and was transferred to the ward. The 
fever was attributed to post operative pyrexia which 
subsided within 24 hours. 
 In the ward the child was observed for one day 
with no further complaints and was discharged home 
to be followed up at the paediatric clinic. 
dIscussIon
Bupivacaine has many applications; in this case it 
was used as infiltrative anaesthesia with the aim of 
achieving post operative analgesia. There are several 
case reports of neurotoxicity and cardiac toxicity in 
adults due to bupivacaine toxicity. Generalised tonic 
clonic seizures have been reported in a 27 year old 
patient following an intrascalene brachial plexus block 
after presumed intravenous injection of bupivacaine 
(5). There have also been case reports of central 
nervous system toxicity and grand mal seizures 
following an accidental intravascular injection of 
bupivacaine (6). However to our knowledge there 
have been no published case reports in the paediatric 
age group. 
 The first symptoms in our patient were noted five 
minutes after the injection of bupivacaine (without 
epinephrine) and lignocaine suggesting excessive 
absorption with consequent cardiovascular and 
neurological toxicity. 
 The toxic dose of bupivacaine has been reported 
at 1.6mg/kg (2). In our patient the dose was given at 
4mg/kg, which was far higher than the calculated 
toxic dose. 
 The convulsions usually appear suddenly and 
can be stopped by use of antiepileptic agents like 
diazepam and barbiturates (7). Our patient was 
initially given phenytoin which acts by blocking 
sodium channels and was thought to have potentiated 
the neurotoxicity. Subsequently the seizures resolved 
with diazepam. Levobupivacaine the S(-) enantiomer, 
though less toxic has affinity for neuronal Na+ 
channels comparable with R (+) enantiomer (8). 
 An electroencephalogram (EEG) was not 
performed on our patient as it was handled as an acute 
emergency and the seizures resolved within a few 
hours. Of note is that this is the very first paediatric 
patient and hence no case reports were found to show 
the value of A EEG in the diagnosis of bupivacaine 
toxicity or determining its prognosis. Further case 
reports or studies are required. 
 The cardiovascular effects are as a result 
of myocardial depression and vasodilatation. A 
combination of the above can lead to hypotension which 
can be life threatening (6). The first cardiac symptoms 
were noted within five minutes after injection of 
bupivacaine, suggesting excessive absorption from 
the site with consequent cardiotoxocity. 
 Soon after the initiation of 20% intravenous lipid 
the cardiac symptoms return to normal. The proposed 
mechanism is that lipid infusion accelerates the 
decline in bupivacaine myocardial content (reduced 
tissue binding) by creating a lipid phase that extracts 
the lipid-soluble bupivacaine molecules from the 
aqueous plasma phase (10). A beneficial energetic-
metabolic effect may also occur. In our patient the 
lipid infusion was used in a peri arrest situation. 
 After the infusion of lipid at a bolus of 9mls 
(1.5mls/kg), cardiac function was restored. This was 
followed by a lipid infusion at 0.25ml/kg/min. Four 
hours after the infusion child’s neurologic status had 
stabilised. We did not measure plasma bupivacaine 
concentrations hence we are unable to comment on 
the effect of intralipid on the serum concentration of 
the drug. 
 
In conclusion, we concur with Picard and group that 
lipid emulsion should be routinely kept in hospitals 
for local anaesthetic toxicity. Lipid rescue has not been 
proven to be unquestionably superior to orthodox 
treatment for local anaesthetic intoxication in humans 
but experimental models and human case reports are 
increasingly suggestive (9). 
 Because of the challenges in diagnosing local 
anesthetic toxicity and the paucity of data on the use 
of intralipid infusion in its management, we should 
continue to collate its reported uses in order to reach 
a consensus on the efficacy and aptness of this unique 
treatment. 
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